T-Ray Science, Inc.

T-Ray Science, Inc.

July 14, 2010 17:30 ET

T-Ray Science, Inc. Announces Non-Brokered Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 14, 2010) - T-Ray Science, Inc. (TSX VENTURE:THZ) announces that it intends to complete a non-brokered private placement of up to 3,000,000 units at a price of $0.22 per unit for proceeds of up to $660,000 (the "Offering"). Each unit will comprise of one common share and one half common share purchase warrant (the "Warrants"). Each full Warrant will entitle the holder to purchase one common share at $0.30 per share with an expiry date of 12 months from the closing of the private placement. Closing of the Private Placement is scheduled on or before August 15, 2010 or at any other such time as the Company may decide, subject to the approval of the TSX Venture Exchange and other customary conditions. The common shares will be subject to a four month statutory hold period.

The net proceeds of the private placement will be used to fund the Company's internal operations and working capital requirements. Commissions shall be paid in connection with the private placement consisting of 8% of the gross proceeds of the Offering, and brokers warrants entitling the holder thereof to acquire Shares in an amount equal to 8% of the number of Shares sold by the Broker, which broker warrants shall have the same terms as the Warrants. Finder's Fees may be paid in connection with the private placement in accordance with TSX Venture Exchange policy.

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company centered on the commercialization of an innovative skin cancer detection system for the early diagnosis and treatment of all significant forms of skin cancer. (Including: melanoma, basal cell carcinoma and squamous cell carcinoma).

The Company's patented imaging and spectroscopy technologies are the foundation for the development of the company's non-invasive, in vivo skin cancer detection and delineation system. This diagnostic tool will deliver significant clinical impact through improved patient outcomes, and will reduce healthcare costs by eliminating the need for most biopsies. The platform technology is extensible to other forms of cancer including gastro-intestinal and cervical cancers.

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of THz based products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information